Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


08.07.2019

1 Am J Clin Pathol
2 Am J Respir Cell Mol Biol
2 Am J Respir Crit Care Med
3 Anticancer Res
1 Arch Bronconeumol
2 BMC Cancer
1 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Res
1 Cancer Sci
1 Carcinogenesis
2 Clin Cancer Res
1 Clin Lung Cancer
1 Clin Nucl Med
1 Eur J Cancer
3 Eur Respir J
2 Int J Cancer
1 Int J Radiat Oncol Biol Phys
2 J Cancer Res Clin Oncol
1 J Clin Invest
3 J Thorac Cardiovasc Surg
4 J Thorac Oncol
2 Lancet Oncol
1 Lung Cancer
1 Mol Carcinog
1 N Engl J Med
2 Nat Med
1 Oncogene
2 Oncol Rep
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Pathol

  1. TSENG LH, De Marchi F, Pallavajjalla A, Rodriguez E, et al
    Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens.
    Am J Clin Pathol. 2019 Jul 2. pii: 5527153. doi: 10.1093.
    PubMed     Text format     Abstract available


    Am J Respir Cell Mol Biol

  2. OBRAZTSOVA K, Evans J, Krymskaya VP
    Syndecan-2: Old Player in a New Field.
    Am J Respir Cell Mol Biol. 2019;60:611-612.
    PubMed     Text format    

  3. LEVINE AR, Bain W, Bednash JS, Gladwin MT, et al
    AMP Kinase Activation Attenuates Cardiac Remodeling in Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction; Lung Epithelial Progenitor Cells in Alveolar Regeneration; and Drug Discovery and Novel Therapies for Lung Cancer.
    Am J Respir Cell Mol Biol. 2019;60:244-247.
    PubMed     Text format    


    Am J Respir Crit Care Med

  4. ALLINSON JP, Brown J, Gibb K, Navani N, et al
    Immunotherapy in Non-Small Cell Lung Cancer. Which Patients and at Which Stage?
    Am J Respir Crit Care Med. 2019;199:1277-1279.
    PubMed     Text format    

  5. TAGUCHI A, Arenberg D
    Harnessing Immune Response to Malignant Lung Nodules. Promise and Challenges.
    Am J Respir Crit Care Med. 2019;199:1184-1186.
    PubMed     Text format    


    Anticancer Res

  6. DRAG-ZALESINSKA M, Saczko J, Choromanska A, Szewczyk A, et al
    Cisplatin and Vinorelbine -Mediated Electrochemotherapeutic Approach Against Multidrug Resistant Small Cell Lung Cancer (H69AR) In Vitro.
    Anticancer Res. 2019;39:3711-3718.
    PubMed     Text format     Abstract available

  7. FUJITA K, Uchida N, Yamamoto Y, Kanai O, et al
    Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies.
    Anticancer Res. 2019;39:3917-3921.
    PubMed     Text format     Abstract available

  8. GIULIANI J, Bonetti A
    Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors.
    Anticancer Res. 2019;39:3961-3965.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  9. DE VEGA SANCHEZ B, Disdier Vicente C, Roig Figueroa V, Lopez Castro R, et al
    Association Between Idiopathic Pulmonary Fibrosis and Lung Cancer.
    Arch Bronconeumol. 2019 Jun 28. pii: S0300-2896(19)30269.
    PubMed     Text format    


    BMC Cancer

  10. ZHAO J, Teng H, Zhao R, Ding W, et al
    Malignant perivascular epithelioid cell tumor of the lung synchronous with a primary adenocarcinoma: one case report and review of the literature.
    BMC Cancer. 2019;19:235.
    PubMed     Text format     Abstract available

  11. DUBAERE E, Goffaux M, Wanet M, Bihin B, et al
    Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
    BMC Cancer. 2019;19:639.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  12. ROYS A, Chang X, Liu Y, Xu X, et al
    Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer.
    Cancer Chemother Pharmacol. 2019 Jun 29. pii: 10.1007/s00280-019-03902.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  13. KACHURI L, Helby J, Bojesen SE, Christiani DC, et al
    Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer.
    Cancer Epidemiol Biomarkers Prev. 2019;28:1228-1237.
    PubMed     Text format     Abstract available


    Cancer Res

  14. SHAHABI S, Kumaran V, Castillo J, Cong Z, et al
    LINC00261 Is an Epigenetically Regulated Tumor Suppressor Essential for Activation of the DNA Damage Response.
    Cancer Res. 2019;79:3050-3062.
    PubMed     Text format     Abstract available

  15. DAVALOS V, Esteller M
    Disruption of Long Noncoding RNAs Targets Cancer Hallmark Pathways in Lung Tumorigenesis.
    Cancer Res. 2019;79:3028-3030.
    PubMed     Text format     Abstract available


    Cancer Sci

  16. HIRASHIMA T, Satouchi M, Hida T, Nishio M, et al
    Osimertinib for Japanese Patients with T790M-positive Advanced Non-Small Cell Lung Cancer: A Pooled Subgroup Analysis.
    Cancer Sci. 2019 Jul 2. doi: 10.1111/cas.14120.
    PubMed     Text format     Abstract available


    Carcinogenesis

  17. JIN M, Ren J, Luo M, You Z, et al
    Long noncoding RNA JPX correlates with poor prognosis and tumor progression in non-small cell lung cancer by interacting with miR-145-5p and CCND2.
    Carcinogenesis. 2019 Jun 28. pii: 5525190. doi: 10.1093.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  18. MA PC
    (Not Giving Up) The Marathon Race of MET Targeting Therapy: Are We There Yet?
    Clin Cancer Res. 2019;25:2375-2378.
    PubMed     Text format     Abstract available

  19. VAN CUTSEM E, Karaszewska B, Kang YK, Chung HC, et al
    A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors.
    Clin Cancer Res. 2019;25:2414-2423.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  20. LACOUR M, Hiltbrunner S, Lee SY, Soltermann A, et al
    Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence.
    Clin Lung Cancer. 2019 Jun 5. pii: S1525-7304(19)30140.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  21. ZHENG Y, Wang H, Tan H, Cui X, et al
    Evaluation of Lung Cancer and Neuroendocrine Neoplasm in a Single Scan by Targeting Both Somatostatin Receptor and Integrin alphavbeta3.
    Clin Nucl Med. 2019 Jul 2. doi: 10.1097/RLU.0000000000002680.
    PubMed     Text format     Abstract available


    Eur J Cancer

  22. LINDSAY CR, Blackhall FH, Carmel A, Fernandez-Gutierrez F, et al
    EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.
    Eur J Cancer. 2019;117:60-68.
    PubMed     Text format     Abstract available


    Eur Respir J

  23. AMAT B, Sapia S
    A journey to the centre of the mediastinal lymph nodes.
    Eur Respir J. 2019;53.
    PubMed     Text format    

  24. DENG HY, Zhou Q
    Lobectomy should remain the first choice for treating early stage nonsmall cell lung cancer.
    Eur Respir J. 2019;54.
    PubMed     Text format    

  25. KRISTOF AS, Ortega VE
    The discovery of novel mechanisms for lymphangioleiomyomatosis pathogenesis through GWAS: a rarity in rare respiratory disorders.
    Eur Respir J. 2019;53.
    PubMed     Text format    


    Int J Cancer

  26. HUANG JY, Larose TL, Luu HN, Wang R, et al
    Circulating markers of cellular immune activation in pre-diagnostic blood sample and lung cancer risk in the Lung Cancer Cohort Consortium (LC3).
    Int J Cancer. 2019 Jul 5. doi: 10.1002/ijc.32555.
    PubMed     Text format     Abstract available

  27. ZHANG L, Yang Y, Chai L, Bu H, et al
    FRK plays an oncogenic role in nonsmall cell lung cancer by enhancing the stemness phenotype via induction of metabolic reprogramming.
    Int J Cancer. 2019 Jun 28. doi: 10.1002/ijc.32530.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  28. SAMPATH S, Rahmanuddin S, Sahoo P, Frankel P, et al
    Change in apparent diffusion coefficient is associated with local failure after stereotactic body radiation therapy for non-small cell lung cancer: a prospective clinical trial.
    Int J Radiat Oncol Biol Phys. 2019 Jul 1. pii: S0360-3016(19)33424.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  29. SHEN J, Xu J, Chen B, Ma D, et al
    Elevated integrin alpha6 expression is involved in the occurrence and development of lung adenocarcinoma, and predicts a poor prognosis: a study based on immunohistochemical analysis and bioinformatics.
    J Cancer Res Clin Oncol. 2019;145:1681-1693.
    PubMed     Text format     Abstract available

  30. OMORI T, Aokage K, Nakamura H, Katsumata S, et al
    Growth patterns of small peripheral squamous cell carcinoma of the lung and their impacts on pathological and biological characteristics of tumor cells.
    J Cancer Res Clin Oncol. 2019;145:1773-1783.
    PubMed     Text format     Abstract available


    J Clin Invest

  31. SUZUKI M, Cao K, Kato S, Komizu Y, et al
    Targeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells.
    J Clin Invest. 2019;130.
    PubMed     Text format    


    J Thorac Cardiovasc Surg

  32. DONINGTON JS, Martin LW
    Commentary: The need to RIOT (return to intended oncologic treatment) after lung cancer surgery.
    J Thorac Cardiovasc Surg. 2019;158:287-288.
    PubMed     Text format    

  33. LUI NS
    Commentary: Should lung cancer screening guidelines go up in smoke?
    J Thorac Cardiovasc Surg. 2019 May 31. pii: S0022-5223(19)31140.
    PubMed     Text format    

  34. BRAVO-INIGUEZ CE, Fox SW, De Leon LE, Tarascio JN, et al
    Cumulative nonsmoking risk factors increase the probability of developing lung cancer.
    J Thorac Cardiovasc Surg. 2019 May 18. pii: S0022-5223(19)31038.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  35. FOSTER CC, Pitroda SP, Weichselbaum RR
    Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jul 1. pii: S1556-0864(19)30410.
    PubMed     Text format    

  36. BLACK WC, Chiles C, Church TR, Gareen IF, et al
    Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial National Lung Screening Trial Writing Team (1).
    J Thorac Oncol. 2019 Jun 13. pii: S1556-0864(19)30473.
    PubMed     Text format     Abstract available

  37. NAITO T, Udagawa H, Sato J, Horinouchi H, et al
    A minimum of 100 tumor cells in a single biopsy sample is required to assess programmed cell death ligand 1 expression in predicting patient response to nivolumab treatment in non-squamous non-small cell lung carcinoma.
    J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30501.
    PubMed     Text format     Abstract available

  38. BAUER TM, Besse B, Martinez-Marti A, Trigo JM, et al
    Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30503.
    PubMed     Text format     Abstract available


    Lancet Oncol

  39. LUO YH, Luo L, Wampfler JA, Wang Y, et al
    5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.
    Lancet Oncol. 2019 Jun 26. pii: S1470-2045(19)30329.
    PubMed     Text format     Abstract available

  40. BERG CD
    Improving selection of individuals into lung cancer screening programmes.
    Lancet Oncol. 2019 Jun 26. pii: S1470-2045(19)30411.
    PubMed     Text format    


    Lung Cancer

  41. SUH CH, Kim KW, Nishino M
    Reply to the comments on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis i
    Lung Cancer. 2019;127:168.
    PubMed     Text format    


    Mol Carcinog

  42. MA W, Ho DW, Sze KM, Tsui YM, et al
    APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity.
    Mol Carcinog. 2019;58:643-653.
    PubMed     Text format     Abstract available


    N Engl J Med

  43. SALEM JE, Allenbach Y, Vozy A, Brechot N, et al
    Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
    N Engl J Med. 2019;380:2377-2379.
    PubMed     Text format    


    Nat Med

  44. ARDILA D, Kiraly AP, Bharadwaj S, Choi B, et al
    Author Correction: End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography.
    Nat Med. 2019 Jun 28. pii: 10.1038/s41591-019-0536.
    PubMed     Text format     Abstract available

  45. STOWER H
    Evading the immune system.
    Nat Med. 2019;25:710.
    PubMed     Text format    


    Oncogene

  46. SAIGI M, Alburquerque-Bejar JJ, Sanchez-Cespedes M
    Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.
    Oncogene. 2019 Jun 28. pii: 10.1038/s41388-019-0855.
    PubMed     Text format     Abstract available


    Oncol Rep

  47. HUANG WT, He RQ, Li XJ, Ma J, et al
    miR146a5p targets TCSF and influences cell growth and apoptosis to repress NSCLC progression.
    Oncol Rep. 2019;41:2226-2240.
    PubMed     Text format     Abstract available

  48. LI Y, Zhao C, Liu J, Lu Z, et al
    CD1d highly expressed on DCs reduces lung tumor burden by enhancing antitumor immunity.
    Oncol Rep. 2019;41:2679-2688.
    PubMed     Text format     Abstract available


    PLoS One

  49. DACOSTA-NOBLE P, Costantini A, Dumenil C, Dumoulin J, et al
    Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients.
    PLoS One. 2019;14:e0219080.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: